Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

May 31, 2020

Study Completion Date

July 31, 2020

Conditions
Radiation PneumonitisEndostatin
Interventions
DRUG

Endostar

Patients in the observation group were treated with routine radiation pneumonia and Endostar. Endostar usage: continuous intravenous pumping of Endostar(14 doses each time) over 5 days. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.

DRUG

standard SRILI treatment

Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.

Trial Locations (1)

400000

Xinqiao Hospital of Chongqing, Chongqing

All Listed Sponsors
lead

Xinqiao Hospital of Chongqing

OTHER

NCT03796364 - Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis | Biotech Hunter | Biotech Hunter